000297995 001__ 297995
000297995 005__ 20250203135910.0
000297995 0247_ $$2pmid$$apmid:39824235
000297995 0247_ $$2ISSN$$a0531-5565
000297995 0247_ $$2ISSN$$a1873-6815
000297995 0247_ $$2doi$$a10.1016/j.exger.2025.112684 
000297995 0247_ $$2doi$$a10.1016/j.exger.2025.112684
000297995 0247_ $$2altmetric$$aaltmetric:173429399
000297995 037__ $$aDKFZ-2025-00170
000297995 041__ $$aEnglish
000297995 082__ $$a610
000297995 1001_ $$aLohner, Valerie$$b0
000297995 245__ $$aAssociations of blood-based biomarkers of neurodegenerative diseases with mortality, cardio- and cerebrovascular events in persons with chronic coronary syndrome.
000297995 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000297995 3367_ $$2DRIVER$$aarticle
000297995 3367_ $$2DataCite$$aOutput Types/Journal article
000297995 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738587517_22142
000297995 3367_ $$2BibTeX$$aARTICLE
000297995 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000297995 3367_ $$00$$2EndNote$$aJournal Article
000297995 500__ $$a#LA:C120# / Volume 200, February 2025, 112684
000297995 520__ $$aIn light of growing evidence highlighting interactions between cardiac and brain health, we investigated associations of biomarkers of neurodegenerative diseases with adverse outcomes (all-cause and cardiovascular mortality, major cardiovascular events, and stroke) in persons with chronic coronary syndrome (CCS).We used data from a cohort of persons with CCS for whom major adverse events were recorded over a follow-up of 20 years. We measured biomarkers of neurodegenerative diseases in baseline blood samples, using the Single-Molecule Array Technology on a HD-1 Analyzer. These include biomarkers of neuronal (neurofilament light chain (NfL) (n = 379)) and glial neurodegeneration (glial fibrillary acidic protein (GFAP) (n = 379)), and Alzheimer's disease pathology (phosphorylated tau181 (n = 379), total tau (n = 377), and amyloid β (Aβ40, Aβ42, Aβ42/Aβ40) (n = 377)). We applied Cox-proportional hazards models to evaluate associations of these biomarkers with adverse outcomes, adjusting for covariates and exploring interactions with apolipoprotein E (ApoE) ε4 genotype.Participants with higher NfL levels had increased rates of all-cause and cardiovascular mortality (Hazard ratio per increase by one standard deviation (95 % confidence interval): all-cause mortality: 1.36 (1.10-1.68); cardiovascular mortality: 1.42 (1.05-1.93)). The Aβ40/Aβ42-ratio was linked to incident stroke (0.72 (0.52-1.00)). Associations of GFAP with all-cause mortality and incident stroke were depending on ApoE ε4 genotype. The other biomarkers were not significantly associated with the studied outcomes.In persons with CSS, NfL and the Aβ40/Aβ42-ratio were related to mortality and incident stroke, respectively, whereas associations of GFAP with adverse outcomes varied by ApoE genotype. These biomarkers might play a role in linking aging, cardiovascular and neurodegenerative diseases.
000297995 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000297995 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000297995 650_7 $$2Other$$aBlood-based biomarkers of neurodegenerative diseases
000297995 650_7 $$2Other$$aCerebrovascular events
000297995 650_7 $$2Other$$aChronic coronary syndrome
000297995 650_7 $$2Other$$aCoronary heart disease
000297995 650_7 $$2Other$$aEpidemiology
000297995 650_7 $$2Other$$aMajor cardiovascular events
000297995 650_7 $$2Other$$aMortality
000297995 7001_ $$aPerna, Laura$$b1
000297995 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b2$$udkfz
000297995 7001_ $$aPerneczky, Robert$$b3
000297995 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000297995 7001_ $$0P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9$$aMons, Ute$$b5$$eLast author$$udkfz
000297995 773__ $$0PERI:(DE-600)2005397-6$$a10.1016/j.exger.2025.112684$$p112684$$tExperimental gerontology$$v200$$x0531-5565$$y2025
000297995 909CO $$ooai:inrepo02.dkfz.de:297995$$pVDB
000297995 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000297995 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000297995 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1b59582b6c05ac4e57aa8b90dd9667f9$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000297995 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000297995 9141_ $$y2025
000297995 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-02$$wger
000297995 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-06-13T12:49:31Z
000297995 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-06-13T12:49:31Z
000297995 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-06-13T12:49:31Z
000297995 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
000297995 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
000297995 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPrimäre Krebsprävention$$x0
000297995 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000297995 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPrimäre Krebsprävention$$x1
000297995 980__ $$ajournal
000297995 980__ $$aVDB
000297995 980__ $$aI:(DE-He78)C070-20160331
000297995 980__ $$aI:(DE-He78)C120-20160331
000297995 980__ $$aUNRESTRICTED